Potential ROS-reducing agents studied in preclinical models
| References . | Agent . | Mechanism . | Stage . | Result . |
|---|---|---|---|---|
| Ref. 37 | Monomethyl fumorate | Ntf2 induction and HbF induction | SCD mice | Reduces sickle retinopathy |
| Ref. 38 | 2-Cyano-3,12 dioxooleana-1,9 diene-28-imidazolide (Nrf2 inducer) | Nrf2 induction | SCD mice | Reduces inflammation and organ damages |
| Ref. 40 | INK128 and sirolimus | Mammalian target of rapamycin inhibition | SCD mice | Reduces organ damages |
| Ref. 39 | Sildenafil | Promotes endothelial NO synthase and inhibits NADPH oxidation | SCD mice | Protects vascular endothelium |
| Ref. 11 | RN-1 (LSD-1 inhibitor) | Mitophagy induction and reduces SCD-RBC ROS | SCD mice | Increases SCD RBCs lifespan |
| Ref. 11 | Sirolimus (mammalian target of rapamycin inhibitor) | Mitophagy induction and reduces SCD-RBC ROS | SCD mice | Increases SCD RBCs lifespan |
| References . | Agent . | Mechanism . | Stage . | Result . |
|---|---|---|---|---|
| Ref. 37 | Monomethyl fumorate | Ntf2 induction and HbF induction | SCD mice | Reduces sickle retinopathy |
| Ref. 38 | 2-Cyano-3,12 dioxooleana-1,9 diene-28-imidazolide (Nrf2 inducer) | Nrf2 induction | SCD mice | Reduces inflammation and organ damages |
| Ref. 40 | INK128 and sirolimus | Mammalian target of rapamycin inhibition | SCD mice | Reduces organ damages |
| Ref. 39 | Sildenafil | Promotes endothelial NO synthase and inhibits NADPH oxidation | SCD mice | Protects vascular endothelium |
| Ref. 11 | RN-1 (LSD-1 inhibitor) | Mitophagy induction and reduces SCD-RBC ROS | SCD mice | Increases SCD RBCs lifespan |
| Ref. 11 | Sirolimus (mammalian target of rapamycin inhibitor) | Mitophagy induction and reduces SCD-RBC ROS | SCD mice | Increases SCD RBCs lifespan |